Placenta protein may hold clues to preeclampsia
NCT ID NCT06668545
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study investigated levels of a protein called CD71 in placentas from 39 women with preeclampsia and 39 healthy pregnant women. Researchers also looked at newborn outcomes. The goal was to better understand how preeclampsia develops. No treatment was tested; this is a knowledge-gathering study.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help identify new biomarkers for preeclampsia, potentially leading to earlier diagnosis or better management.
- What could go wrong
- This is a small, completed observational study (39 participants) that only looks at tissue samples. It does not test any treatment, so any practical benefits are far off and uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
39 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Preeclampsi Patients
- Ages
-
18 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy pregnancy under 37 weeks * Age range 18-50 * Being literate in Turkish * Not having any additional disease * Agreeing to participate in the study Exclusion Criteria: * High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.) * Multiple pregnancy * Pregnant women under the age of 18 * Smoking * Medication use (excluding routinely used food supplements during pregnancy) * Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.) * Immunosuppressive use * Presence of active or chronic infection * Presence of active or chronic inflammatory disease * Patients who gave birth at an external center or later chose to withdraw from the study * Patients who did not have any exclusion criteria at the time of Preeclampsi or when blood was drawn for the control group, but who later developed any exclusion criteria. * Premature birth of patients included in the control group
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Placenta diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kemal Sarsmaz
Manisa, Yunusemre, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a fetal heart ultrasound index predict trouble in High-Risk pregnancies?
- A bracelet and a blood pressure cuff: a simple plan to protect new mothers at risk
- Can a Light-Based scan spot preeclampsia before it strikes?
- Can a TB infection leave a mark on the placenta?
- Can a malaria drug help prevent preeclampsia?
- Which drug best steadies blood pressure during C-Section in preeclampsia?